From: Differential diffusion of pharmaceutical innovations in a mixed market middle - income economy
Model 3 | Model 3(a) and Model 3(b) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
 |  |  |  |  | Public | Private | ||||
Variable | Coefficient | Â | Standard Error | Variable | Coefficient | Â | Standard Error | Coefficient | Â | Standard Error |
Intercept | 1.892 | Â | (2.124) | Intercept | 4.299 | Â | (3.509) | -0.768 | Â | (2.189) |
Drug characteristic | ||||||||||
 Ln price per DDD | -1.186 | ** | (0.379) | Ln price per DDD | -1.588 | * | (0.661) | -0.821 |  | (0.405) |
Structure and environment characteristics | ||||||||||
 Generic share (DDD) | -2.222 | * | (1.062) | Generic share (DDD) | -4.279 | *** | (0.623) | -0.256 |  | (0.492) |
 Market concentration (HHI) | -3.094 | * | (1.314) | Market concentration (HHI) | -4.194 | ** | (1.441) | -2.263 |  | (1.134) |
Year after registration | ||||||||||
 Year 1 | 1.566 | ** | (0.495) | Year 1 | 1.341 | *** | (0.267) | 1.826 | *** | (0.511) |
 Year 2 | 2.530 | *** | (0.460) | Year 2 | 2.504 | *** | (0.187) | 2.568 | *** | (0.491) |
 Year 3 | 2.696 | *** | (0.519) | Year 3 | 2.786 | *** | (0.278) | 2.636 | *** | (0.608) |
 Year 4 | 2.959 | *** | (0.563) | Year 4 | 3.023 | *** | (0.434) | 3.008 | *** | (0.587) |
 Year 5 | 3.199 | *** | (0.581) | Year 5 | 3.015 | *** | (0.382) | 3.540 | *** | (0.601) |
R – squared | 0.788 |  |  | R - squared | 0.766 |  |  | 0.780 |  |  |
Corr (u_i, Xb) | -0.535 | Â | Â | Corr (u_i, Xb) | -0.855 | Â | Â | 0.284 | Â | Â |
Rho | 0.841 | Â | Â | Rho | 0.932 | Â | Â | 0.859 | Â | Â |
Number of observations | 202 | Â | Â | Number of observations | 93 | Â | Â | 109 | Â | Â |